Halozyme Therapeutics, Inc. (HALO - Free Report) is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HALO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Halozyme could be a solid choice for investors.
Current Quarter Estimates for HALO
In the past 30 days, two estimates have gone higher for Halozyme while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 16 cents a share 30 days ago, to 25 cents today, a move of 56.3%.
Current Year Estimates for HALO
Meanwhile, Halozyme’s current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to none, lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 64 cents per share 30 days ago to 75 cents per share today, an increase of 17.2%.
Halozyme Therapeutics, Inc. Price and Consensus
The stock has also started to move higher lately, adding 30.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>